– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill – AbbVie announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug… Read More
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six years and… Read More
U.S. Customs and Border Protection (CBP) has issued guidance implementing tariff-related elements of the U.S.–EU Framework Agreement on Reciprocal, Fair, and Balanced Trade, which was announced on August 21, 2025,… Read More
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by 2027 Milestone marks progress on AbbVie’s long-term… Read More
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned… Read More
